The Research Support Services Core provides administrative and budget management support for each Project and Core so that research goals may be achieved. Specific services are as follows: 1. Administrative and secretarial a) Organize the monthly scientific meeting of PPG investigators, including WebEx arrangements b) Coordinate the annual meeting of PPG investigators with Ext. Advisory Committee, and concomitant meeting of all NANT site principal investigators in Los Angeles. c) Assist with the Clinical Trials Agreements for the 15 NANT Consortium institutions and any industry sponsored NANT clinical trials d) Assist Project and Core Leaders with the preparation of grants and annual progress report to NCI e) Act as a liaison between CHLA, USC, and UCSF to facilitate subcontract agreements f) Assist Dr. Seeger with annual review of each Project and Core taking into account the External Scientific Review Committee written report, peer reviewed publications, presentations at scientific meetings, generation of phase I clinical protocols g) Provide administrative support to NANT Data Safety Monitoring Board(DSMB), Scientific Review Committee, and Study Management Committees, and assist with development of NANT SOP's;these are key components of Project 4 clinical trials consortium h) Maintain and upgrade NANT website (www.nant.org) as needed;website provides critical information tool for NANT clinical trials consortium i) Insure that all regulatory and compliance requirements are met for animal experimentation and human investigations j) Provide miscellaneous administrative support for Project 1- 4 2. Budget management a) Manage budget for all Projects and Cores b) Manage disbursements of funds for subcontracts with external institutions (USC, UCSF) and for capitation and correlative specimens to NANT consortium institutions c) Reimbursements for participants in Annual PPG and NANT meeting d) Honoraria for NANT DSMB members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA081403-13
Application #
8378049
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
13
Fiscal Year
2012
Total Cost
$35,327
Indirect Cost
Name
Children's Hospital of Los Angeles
Department
Type
DUNS #
052277936
City
Los Angeles
State
CA
Country
United States
Zip Code
90027
DuBois, Steven G; Marachelian, Araz; Fox, Elizabeth et al. (2016) Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol 34:1368-75
Trieu, Megan; DuBois, Steven G; Pon, Elizabeth et al. (2016) Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer 63:436-42
DuBois, Steven G; Groshen, Susan; Park, Julie R et al. (2015) Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 21:2715-21
Chen, Justin; Hackett, Christopher S; Zhang, Shile et al. (2015) The genetics of splicing in neuroblastoma. Cancer Discov 5:380-95
Yanik, Gregory A; Villablanca, Judith G; Maris, John M et al. (2015) 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant 21:673-81
HaDuong, Josephine H; Blavier, Laurence; Baniwal, Sanjeev K et al. (2015) Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis. Int J Cancer 137:797-809
Wang, L L; Teshiba, R; Ikegaki, N et al. (2015) Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study. Br J Cancer 113:57-63
DuBois, S G; Allen, S; Bent, M et al. (2015) Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer 112:644-9
Cage, Tene Aneka; Chanthery, Yvan; Chesler, Louis et al. (2015) Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer. Front Oncol 5:111
Huang, Shih-ying; Bolch, Wesley E; Lee, Choonsik et al. (2015) Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol 17:284-94

Showing the most recent 10 out of 131 publications